Andreas Halvorsen’s 4D Molecular Therapeutics FDMT Stock Holding History

Andreas Halvorsen’s Portfolio FDMT Stock Details FDMT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q3	–	Sell	-2,934,914	Closed	-$61.6M	–	91
2024 Q2	$61.6M	Hold	2,934,914	–	–	0.24%	66
2024 Q1	$93.5M	Sell	2,934,914 -1,853,000	-39%	-$47.3M	0.35%	56
2023 Q4	$97M	Hold	4,787,914	–	–	0.36%	56
2023 Q3	$61M	Hold	4,787,914	–	–	0.25%	60
2023 Q2	$86.5M	Buy	4,787,914 +850,000	+22%	+$15.6M	0.35%	57
2023 Q1	$67.7M	Hold	3,937,914	–	–	0.32%	56
2022 Q4	$87.5M	Hold	3,937,914	–	–	0.44%	50
2022 Q3	$31.7M	Hold	3,937,914	–	–	0.15%	74
2022 Q2	$27.5M	Hold	3,937,914	–	–	0.13%	75
2022 Q1	$59.5M	Hold	3,937,914	–	–	0.24%	73
2021 Q4	$86.4M	Hold	3,937,914	–	–	0.25%	75
2021 Q3	$106M	Hold	3,937,914	–	–	0.29%	69
2021 Q2	$94.8M	Hold	3,937,914	–	–	0.29%	64
2021 Q1	$171M	Hold	3,937,914	–	–	0.51%	52
2020 Q4	$163M	Buy	+3,937,914	New	+$163M	0.45%	56

Other funds holding FDMT

BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

VR Adviser New York $3.3B AUM 525.74% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Andreas Halvorsen's FDMT Position: Q3 2024 in Review

Andreas Halvorsen sold out of 4D Molecular Therapeutics (FDMT) in Q3 2024, closing a stake of 2,934,914 shares — an estimated $61.6M sold.

Andreas Halvorsen first reported a position in FDMT in Q4 2020 and held it in 15 quarters. The position peaked at $171M in Q1 2021. 140 funds tracked by Wall St. Rank hold FDMT as of Q3 2024.

Andreas Halvorsen reported no remaining 4D Molecular Therapeutics position as of Q3 2024 after selling out during the quarter.
Andreas Halvorsen sold 2,934,914 4D Molecular Therapeutics shares in Q3 2024, an estimated $61.6M.
Andreas Halvorsen first reported a position in 4D Molecular Therapeutics in Q4 2020 and held it in 15 quarters.
Andreas Halvorsen's 4D Molecular Therapeutics position peaked at $171M in Q1 2021.
140 funds tracked by Wall St. Rank held 4D Molecular Therapeutics as of Q3 2024.

Based on Viking Global Investors's 13F filing for Q3 2024, filed 14 Nov 2024.